SecurityBKJ / Bancorp of New Jersey, Inc. (059915108)
President and CEOGRAVES NANCY E
IndustryState Commercial Banks
Institutional Owners21
Institutional Shares774,322 - 11.14%
Common Shares Outstanding6,948,278 shares (as of 2018-03-31)
Institutional Value$ 12,876,000 USD

Institutional Stock Ownership and Shareholders

BKJ / Bancorp of New Jersey, Inc. Institutional Ownership

Bancorp of New Jersey, Inc. (AMEX:BKJ) has 21 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 774,322 shares. Largest shareholders include Clover Partners, L.P., Alliancebernstein L.p., River Oaks Capital LLC, Vanguard Group Inc, Context BH Capital Management, LP, Bank of New York Mellon Corp, Dimensional Fund Advisors Lp, Morgan Stanley, Sei Investments Co, and F3logic, Llc.
Bancorp of New Jersey, Inc. (AMEX:BKJ) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/bkj"><img src="https://images.fintel.io/us-bkj-so.png" alt="BKJ / Bancorp of New Jersey, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR Context BH Capital Management, LP 30,897 30,897 0.00 564 514 -8.87
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 262 4
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 0 0 0 0
2018-05-14 13F-HR Adviser Investments LLC 90 1
2018-05-15 13F-HR Clover Partners, L.P. 433,480 433,480 0.00 7,911 7,217 -8.77
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 15,530 18,441 18.74 283 307 8.48
2018-05-15 13F-HR DEUTSCHE BANK AG\ 3,102 2,600 -16.18 56 43 -23.21
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 103 103 0.00 2 2 0.00
2018-05-15 13F-HR Bank of New York Mellon Corp 86,397 22,631 -73.81 1,577 376 -76.16
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 0 1,692 0 28
2018-05-14 13F-HR MORGAN STANLEY 17,036 16,750 -1.68 311 279 -10.29
2017-02-10 13F-HR BlackRock Investment Management, LLC 719 719 0.00 8 10 25.00
2018-04-23 13F-HR F3logic, Llc 11,550 192
2018-05-15 13F-HR UBS Group AG 970 0 -100.00 18 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 6,485 4,419 -31.86 118 74 -37.29
2017-02-10 13F-HR BlackRock Fund Advisors 1,077 1,617 50.14 12 22 83.33
2018-05-15 13F-HR VANGUARD GROUP INC 77,156 52,349 -32.15 1,408 871 -38.14
2018-05-11 13F-HR SEI INVESTMENTS CO 13,395 11,550 -13.77 269 192 -28.62
2018-05-14 13F-HR River Oaks Capital LLC 76,453 76,453 0.00 1,395 1,273 -8.75
2018-05-15 13F-HR BARCLAYS PLC 297 5
2017-02-10 13F-HR BlackRock Advisors LLC 2,128 2,128 0.00 24 29 20.83
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 64,668 86,047 33.06 1,180 1,433 21.44
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 247 247 0.00 5 4 -20.00

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 059915108